Human Papillomavirus Vaccine

Panatto, Donatella; Amicizia, Daniela; Bragazzi, Nicola Luigi; Rizzitelli, Emanuela; Tramalloni, Daniela; Valle, Ivana La; Gasparini, Roberto

doi:10.1016/bs.apcsb.2015.08.004

Cited by 24 publications

(12 citation statements)

References 438 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though most widely used vaccines are the bivalent vaccine against HPV-16 and 18, and the tetra-valent vaccine for genotypes 6, 11, 16 and 18, our results show that other genotypes could be considered for prophylaxis strategies. In relation to this, the nine-valent vaccine also includes HPV-31, 33, 45, 52, and 58 ( Kash et al, 2015 ; Panatto et al., 2015 ).…”

Section: Discussionmentioning

confidence: 99%

Infection and coinfection by human papillomavirus, Epstein–Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study

Vazquez-Guillen

Palacios-Saucedo

Rivera-Morales

et al. 2018

PeerJ

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) is recognized as an important risk factor for laryngeal carcinogenesis. Although HPV-16 and 18 have been strongly implicated, the presence of other high-risk HPV (HR-HPV) genotypes or the coinfection with Epstein-Barr virus (EBV) or Merkel cell polyomavirus (MCPV) may increase the risk, but their etiological association has not been definitively established.MethodsWe characterized the genotype-specific HPV and the frequency of EBV and MCPV infections through the detection of their DNA in 195 laryngeal specimens of squamous cell carcinoma (SCC) histologically confirmed.ResultsHPV DNA was detected in 93 (47.7%) specimens. HPV-11 was the most frequent with 68 cases (73.1%), and HPV-52 was the most frequently HR-HPV found with 51 cases, which corresponds to 54.8% of all HPV-positive specimens. EBV DNA was detected in 54 (27.7%) tumor tissue specimens of which 25 (46.3%) were in coinfection with HPV. MCPV DNA was detected only in 11 (5.6%) cases of which 5 (45.4%) were in coinfection with an HR-HPV. No association between the presence of DNA of the three examined viruses and the patient smoking habits, alcohol consumption, age, the keratinization status, differentiation grade, or localization of the tumor in the larynx were found.DiscussionHPV-52 was the most prevalent HR-HPV, which may suggest that this and other genotypes in addition to HPV-16 and 18 could be considered for prophylaxis. However, further studies including non-cancer larynx cases and the evaluation of other molecular markers and viral co-infection mechanisms are needed to determine the role of the different HR-HPV genotypes, EBV, and MCPV in the etiology of SCC of the larynx.

show abstract

Section: Discussionmentioning

confidence: 99%

Infection and coinfection by human papillomavirus, Epstein–Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study

Vazquez-Guillen

Palacios-Saucedo

Rivera-Morales

et al. 2018

PeerJ

View full text Add to dashboard Cite

show abstract

“…L2, the minor capsid protein, forms the inner surface of the viral capsid with the N-terminus extending to the capsid surface. L2 contributes to infectivity, viral trafficking, encapsulation of viral DNA, virion release, and the suppression of maturation of Langerhans cells [ 216 , 219 , 220 ]. E1 and E2 play roles in viral replication: E1 encodes a viral-specific helicase necessary for DNA replication and amplification, while E2 participates in viral transcription, replication, and genome partitioning [ 221 ].…”

Section: Human Papillomavirusmentioning

confidence: 99%

“…All of the preventative vaccines are based on synthetic recombinant L1 major capsid protein, arranged in icosahedral virus-like particles [ 211 , 270 ]. A downfall of L1-based vaccines is that they induce HPV type-specific immune responses [ 220 ]. L2 minor capsid protein vaccines are being explored as a potential for broad-spectrum coverage due to the homology of L2 across HPV types.…”

Section: Human Papillomavirusmentioning

confidence: 99%

Viral Oncology: Molecular Biology and Pathogenesis

Mui

Haley

Tyring

2017

JCM

144

147

View full text Add to dashboard Cite

Oncoviruses are implicated in approximately 12% of all human cancers. A large number of the world’s population harbors at least one of these oncoviruses, but only a small proportion of these individuals go on to develop cancer. The interplay between host and viral factors is a complex process that works together to create a microenvironment conducive to oncogenesis. In this review, the molecular biology and oncogenic pathways of established human oncoviruses will be discussed. Currently, there are seven recognized human oncoviruses, which include Epstein-Barr Virus (EBV), Human Papillomavirus (HPV), Hepatitis B and C viruses (HBV and HCV), Human T-cell lymphotropic virus-1 (HTLV-1), Human Herpesvirus-8 (HHV-8), and Merkel Cell Polyomavirus (MCPyV). Available and emerging therapies for these oncoviruses will be mentioned.

show abstract

“…A capsomere is the basic component of the virus capsid. It has only ive L1 copies of the protein, presents similar immunogenicity than an L1 VLP, and can be produced in bacteria [70]. A phase II clinical trial for a HPV 16 L1 capsomere vaccine is currently being conducted (NCT 01355823) [82,86].…”

Section: New Prophylactic Vaccinesmentioning

confidence: 99%

“…A new version of these vaccines including nine diferent types of HPV (6,11,16,18,31,33,45,52, and 58) has also been developed. Since Gardasil 9® seems to be cost efective compared to the previous vaccines [69], it has also been licensed for clinical use [70].…”

Section: Cervarix® and Gardasil®mentioning

confidence: 99%

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Rosales¹,

Rosales²

2017

Vaccines

View full text Add to dashboard Cite

Human papillomaviruses (HPVs) are a large family of double-strand DNA viruses comprising more than 180 types. Infection with HPV is associated with benign and malignant proliferation of skin and mucosae. Low-risk HPVs produce warts, whereas high-risk viruses induce tumors. Because there are no anti-viral drugs for HPV infection, there is a lot of interest in vaccines that can prevent the infection and also in vaccines that can be used to treat established infections and HPV-related tumors. Two prophylactic vaccines have been approved for preventing HPV infection. They seem to be efective when very young people are vaccinated. Unfortunately, many older people are still at risk of infection, mainly in countries where vaccination coverage is not eicient and for those people, novel therapeutic vaccines are being developed. This chapter describes the properties of HPV vaccines used today and the current status of several therapeutic vaccines been developed to treat HPV-induced lesions.

show abstract

Human Papillomavirus Vaccine

Cited by 24 publications

References 438 publications

Infection and coinfection by human papillomavirus, Epstein–Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study

Infection and coinfection by human papillomavirus, Epstein–Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study

Viral Oncology: Molecular Biology and Pathogenesis

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Contact Info

Product

Resources

About